May 26, 2020
New Publication Reveals Real-World Usage of Vibativ® In Patients With Bacteremia Or Endocarditis
May 11, 2020
Vibativ® Sustained Potency Confirmed In Two Surveillance Studies
Mar 23, 2020
Cumberland Pharmaceuticals Announces Initiative To Expand Availability Of VIBATIV® To Treat Hospital-Acquired & Ventilator-Associated Pneumonia Resulting From Coronavirus Infections
Nov 25, 2019
New Study Reveals Real-World Usage of Vibativ® In a Variety Of Infections
Nov 14, 2019
FDA approves new antibacterial drug to treat complicated urinary tract infections as part of ongoing efforts to address antimicrobial resistance
Oct 08, 2019
Vast Therapeutics Receives Qualified Infectious Disease Product Status for BIOC11
Apr 03, 2019
Correvio Announces Xydalba(TM) (Dalbavancin Hydrochloride) Abstracts at ECCMID 2019
Nov 06, 2018
Theravance Biopharma Announces Sale of VIBATIV® (telavancin) to Cumberland Pharmaceuticals
Oct 12, 2018
The Menarini Group Announces Commercial Agreement for Vabomere, Orbactiv and Minocin in 68 Countries
Oct 08, 2018
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek(TM) 2018
Oct 01, 2018
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at IDWeek(TM) 2018
Sep 28, 2018
FDA approves a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation
Apr 23, 2018
Theravance Biopharma Reports Positive New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID(TM) Conference
Apr 17, 2018
Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID(TM) Conference
Apr 12, 2018
Cardiome Announces Fifteen Xydalba(TM) and Zevtera® Abstracts at ECCMID 2018
Mar 22, 2018
Health Canada Accepts Cardiome's Xydalba New Drug Submission and Grants Priority Review
Mar 19, 2018
Amplyx Pharmaceuticals Receives Fourth "Qualified Infectious Disease Product" (QIDP) Designation from the FDA for APX001
Dec 11, 2017
Cardiome Announces Xydalba(TM) Treatment And Patient Experience Presentations At The 2017 National Opat Conference
Oct 31, 2017
Theravance Biopharma Reports Positive New VIBATIV® (telavancin) Data from TOUR(TM) Observational Patient Registry at 2017 CHEST Annual Meeting
Oct 30, 2017
Cardiome Announces Commercial Launch of Xydalba(TM) in Three New European Geographies